Introduction
Retinoids, which are natural and synthetic vitamin A derivatives, have marked effects on cellular proliferation, differentiation and on the immunosystem (1, 2) . The pleiotropic effects of retinoids are mediated by two classes of receptors, retinoic acid receptors (RARs: RARa, RARb and RARg) (3--6) , and retinoid X receptors (RXRs: RXRa, RXRb and RXRg), both of which are members of the steroid/thyroid receptor superfamily of ligand-dependent transcriptional factors (7--9) . The RARs-dependent signalling pathway is mainly transduced through heterodimeric complexes of RAR/RXR promoted by ligand binding to RAR (10) . All-trans retinoic acid (tRA), a natural metabolite of vitamin A, among its several biological effects has been used as a chemotherapeutic agent because of its strong anti-proliferative activity against certain types of cancer (11--13) . As far as the liver is concerned, only limited and somewhat conflicting information are available regarding the effects of tRA on hepatocyte proliferation and carcinogenesis. It was shown that tRA given shortly prior to 2/3 partial hepatectomy (PH) inhibited DNA synthesis in the regenerating rat liver (14) . In the same study, it was suggested that inhibition of liver regeneration could probably occur via repression of the expression of immediate early genes such as c-fos and c-jun. Although the latter study, together with other reports in different cellular types (11--13) , supports the hypothesis that tRA may exert an antitumoral effect through inhibition of cell proliferation, other studies have shown that tRA, while inhibiting the number and size of preneoplastic lesions induced in rat liver by a choline-deficient diet, does not exert any inhibitory effect on the growth of lesions induced by the genotoxic nitroso compound, diethylnitrosamine (DENA) (15) . In addition, other studies have shown that tRA enhanced development of liver tumors following initiation with DENA in B6D2F1/Hsd mice (16) .
Due to the conflicting results about the role of tRA on liver carcinogenic process, and since surprisingly no data are available on the effect of tRA on normal hepatocyte turnover, the main aim of this study was to investigate the effect of a short-term administration of tRA on liver cell proliferation in intact mice.
The need for studies aimed at clarifying the effect of tRA on normal hepatocyte turnover, stems also from the finding that several other ligands of nuclear receptors have been shown to be mitogenic for the liver. Indeed, peroxisome proliferators, thyroid hormone and the halogenated hydrocarbon TCPOBOP are potent primary mitogens for hepatocytes in rats and mice (17--22) ; interestingly, these agents induce proliferation in the absence of modifications of transcription factors (AP-1, NF-kB, STAT3), immediate early genes (c-fos, c-jun, c-myc) and cytokines (interleukin-6, tumor necrosis factor-a), commonly believed to be essential prerequisite for liver regeneration after partial surgical resection of the liver or chemically induced liver cell necrosis (23--28) , indicating that the mitogenic activity of ligands of nuclear receptors involves a signal transduction pathway different from that activated in compensatory liver regeneration (21, 29) .
Our results show clearly that tRA is a powerful inducer of hepatocyte proliferation and that recruitment of hepatocytes into the cell cycle occurs in the absence of any significant evidence of liver cell damage, thus supporting the notion that ligands of nuclear receptors of the superfamily of steroid/thyroid nuclear hormone receptors possess a direct mitogenic activity for rodent hepatocytes.
Materials and methods

Animals
Female CD-1 mice (7--8 weeks old) purchased from Charles River (Milano, Italy) were used in these experiments. The animals were fed a laboratory chow diet provided by Ditta Mucedola (Settimo Milanese, Italy) and had free access to food and water. We followed Guidelines for the Care and Use of Laboratory Animals during the investigation. All experiments were performed in a temperature-controlled room with alternating 12 h dark/light cycles. tRAsupplemented diet (150 mg/kg) and bromodeoxyuridine (BrdU, 1 mg/ml in drinking water) were purchased from Mucedola (Settimo Milanese, Italy) and Sigma Chemical (St Louis, MO), respectively. Hematoxylin and eosin were from Carlo Erba Reagenti (Milano, Italy).
Experimental protocol I
To determine the effect of tRA on normal resting liver, CD-1 mice were fed a tRA-supplemented diet (150 mg/kg) for 1, 2 and 4 weeks. Controls received a basal diet and were killed at the same time points. For determination of hepatocyte proliferation, 1 week before death, mice were given BrdU, dissolved in drinking water (1 mg/ml).
Experimental protocol II
To determine the kinetics of proliferation after tRA feeding, mice were fed a tRA-supplemented diet for 5 days and were killed at 24, 48, 72, 96 and 120 h. BrdU dissolved in drinking water, was given for 24 h before each death. Controls received a laboratory chow diet and were killed at the same time points. To establish whether the increased DNA synthesis observed in the livers of tRA-fed animals was due to liver damage, additional groups of mice were fed tRA for 1, 2, 3, 4, 5 or 7 days. Five animals were killed at each time point. Controls were killed at the same time points.
Histology and immunohistochemistry
Immediately after death, liver sections were fixed in 10% buffered formalin and processed for staining with hematoxylin--eosin or immunohistochemistry. The remaining liver was snap-frozen in liquid nitrogen and kept at À80 C until use. The incidence of apoptotic bodies was determined by scoring 1500--2000 hepatocytes/liver. Four to five mice per group were analysed. Only apoptotic bodies containing nuclear fragments were recorded.
Serum glutamate pyruvate transaminases determination
The activity of serum glutamate pyruvate transaminases (S-GPT) was determined according to a GP-Transaminase Kit (Sigma Diagnostics, St Louis, MO).
Determination of hepatic DNA content
After death, the livers were frozen at À80 C. Total hepatic DNA content was quantitatively assayed by Burton's diphenylamine method (30) .
Western blot analysis
Total cell extracts were prepared from frozen livers powdered in liquid nitrogen-cold mortar. Equal amounts of powder from different animals were resuspended in 1 ml Triton lysis buffer (1% Triton X-100, 50 mM Tris--HCl pH 7.4, 135 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM PMSF, 10 mM NAF, 5 mM iodoacetic acid, 10 mg/ml each of aprotinin, pepstatin and leupeptin). Several protease inhibitors were added to the isolation buffer to minimize protein degradation during the isolation protocol. Extracts were incubated for 30 min on ice, centrifuged at 12 000 r.p.m. at 4 C and the supernatants recovered. All inhibitors used were purchased from Boheringer Mannheim GmbH (Germany) with the following exception: PMSF, NaF and DTT were purchased from Sigma Chemical and iodoacetic acid from ICN Biomedicals (Irvine, CA). The protein concentration of the resulting total extracts was determined according to Bradford (31) using bovine serum albumin as standard (DC Protein Assay, Bio-Rad Laboratories, USA). Nuclear extracts were prepared for the analysis of pRb, p107, p130, p21, p27 and H3. For immunoblot analysis equal amounts (from 100 to 200 mg/lane) of proteins were electrophoresed on SDS-12% or -8% polyacrylamide gels. Acrylamide and bis-acrylamide were purchased from ICN Biomedicals, Irvine, CA. After gels electrotransfer onto nitrocellulose membranes (MSI), to ensure equivalent protein loading and transfer in all lanes, the membranes and the gels were stained with 0.5% (wt/vol) Ponceau S red (ICN Biomedicals) in 1% acetic acid, and with Coomassie Blue (ICN Biomedicals) in 10% acetic acid, respectively. Before staining, gels were fixed in 25% (v/v) isopropanol and 10% (v/v) acetic acid (Sigma Chemicals). After blocking in TBS containing 0.05% Tween 20 (Sigma) and 5% non-fat dry milk, membranes were washed in TBS-T and then incubated with the appropriate primary antibodies diluted in blocking buffer. Whenever possible, the same membrane was used for detection of the expression of different proteins. Depending on the origin of primary antibody, filters were incubated at room temperature with either anti-mouse, anti-rabbit or anti-rat horseradish peroxidase conjugated IgG (Santa Cruz Biotechnology, Santa Cruz, CA). Immunoreactive bands were identified with a chemiluminescence detection system, as described by the manufacturer (Supersignal Substrate, Pierce). When necessary, antibodies were removed from filters by 30 min incubation at 60 C in stripping buffer (100 mM 2-mercaptoethanol, 2% SDS, 62.5 mM Tris--HCl pH 7.6) and the membranes reblotted as above.
Antibodies
For immunoblotting experiments mouse monoclonal antibody directed against Cyclin D1 (72-13 G, Santa Cruz Biotechnology), p21 (Powerclonal, Upstate Biotech, Lake Placid, NY), and p27 (Kip1-p27, Transduction Laboratories, Lexington, KY) were used; rabbit polyclonal antibodies against Cyclin A (C-19), Cyclin E (M-20), p130 (C-20), H3 (FL-136) and the goat polyclonal antibody against p107 (C-18) were from Santa Cruz. The rabbit polyclonal antibody against phospho-Rb (Ser 780) was from Cell Signaling Technology (Beverly, MA).
Statistical analysis
Comparison between treated and control groups were performed by Student's t test.
Results and discussion
To evaluate the effect of tRA on normal hepatocyte turnover, experiments were performed wherein CD-1 mice were fed a basal diet supplemented with 75, 150 and 300 mg/kg of tRA for 5 days. To determine the L.I., tRA-fed mice and controls were given BrdU (1 mg/ml, dissolved in drinking water) all throughout the experimental period. The results showed that the three tRA concentrations induced an almost similar proliferative response (L.I. was 9.5 AE 2.7, 8 AE 1.0 and 11 AE 4.1 versus 0.2 AE 0.06 of controls). Analysis of serum transaminase levels (S-GPT), at the time of death, did not show any significant change compared with control values (IU/l were 12 AE 2, 9 AE 1 and 13 AE 2, respectively, versus 12 AE 1 of controls), clearly demonstrating the absence of liver necrosis. Histological examination of the livers did not reveal any significant increase in the number of apoptotic bodies compared with controls.
As the diet supplemented with 300 mg of tRA caused a 10% loss of body weight, the next experiments, aimed to further characterize the mechanisms of tRA-induced hepatocyte proliferation, were performed using a diet supplemented with 150 mg/kg. This concentration was chosen also in view of its anticarcinogenic effect in the absence of severe toxicity in a rat model of liver carcinogenesis (15) . As shown in Figure 1A , the tRA-supplemented diet resulted in increased mouse hepatocyte proliferation, as monitored by BrdU incorporation into hepatic DNA; the effect of tRA was maximal during the first week (L.I. of 16.5% against 1.7% of control mice; Figure 2A ). At this time point, most of the labelled cells were localized in the midzonal area of the liver lobule with the areas around zone III being relatively unaffected. Nonparenchymal cells were also labelled although at a lower degree. The L.I. was still significantly higher than control values at 2 weeks, with an almost complete return to the values of age-matched controls after 4 weeks ( Figure 2A) ; as expected, an increase in mitotic activity, with a peak at 1 week after tRA treatment, was associated with the increased L.I. (Figures 1B and 2B) .
To determine the timing of tRA-induced hepatocyte entry into DNA synthesis, further studies were performed where mice were given BrdU in drinking water every 24 h for the first 5 days of tRA feeding. Results shown in Figure 3 indicated that DNA synthesis began between 24 and 48 h (L.I. 2.54 versus 0.31% of controls), with a much higher BrdU incorporation between the fourth and fifth day (L.I. 9.75 versus 0.23% of controls).
Next, we asked the question whether the proliferative effect induced by tRA could be the consequence of tRA-induced liver damage and compensatory regeneration or, rather, a direct mitogenic effect. Results indicate that no increase in S-GPT occurred between day 1 and day 7, the values ranging from 5.3 to 7.5 IU/l in tRA-fed mice versus 6.0 to 7.2 IU/l in control mice. Since apoptotic cell death may occur in the absence of changes in the levels of serum transaminases (32), the apoptotic index was determined in liver sections of mice given tRA for 1, 2, 3, 4 and 5 days. Results did not reveal any significant change in the number of hepatocytes undergoing apoptosis compared with controls (apoptotic index in treated and control animals ranged from 0.02 to 0.07%).
Treatment with tRA for 1 week resulted in an increase in liver weight and, most important, in total hepatic DNA content (21.11 AE 0.63 versus 15.67 AE 0.88 mg DNA/100 g body wt of controls), further establishing that the increased proliferative activity of the hepatocytes after tRA feeding is a direct mitogenic effect.
The increased BrdU incorporation seen in the liver of tRAfed mice was associated with increased protein levels of cyclin A, a cell cycle regulatory protein specifically expressed during S phase; indeed, as shown in Figure 4 , cyclin A levels were induced at a significantly higher level in tRA-fed mice starting from day 2 with maximal expression between day 4 and day 5. It has been shown previously that entry of hepatocytes into the cell cycle following treatment with ligands of nuclear receptors is not associated with changes in cytokines, such as tumor necrosis factor-a and interleukin-6, immediate early genes or transcription factors (22--24) , generally observed during liver regeneration after 2/3 PH (25--28); on the other hand, nuclear receptor-mediated proliferation is accompanied by an early increase in the expression of the G 1 cyclin, cyclin D1 (22, 23) . Therefore, we determined the expression of cyclin D1 protein Fig. 1 . Representative microphotography that illustrates the effect of tRA on BrdU incorporation (A) or mitoses (B) in mouse hepatocytes. Mice were fed a tRA-supplemented diet (150 mg/kg) or a basal diet for 1, 2 or 4 weeks. Immediately after the administration of tRA in the diet, mice were given BrdU (1 mg/ml) in drinking water for 7 days, during the first, the second or the fourth week (Â200, sections counterstained with hematoxylin). CO, Controls; tRA, all-trans-retinoic acid.
in the liver of tRA-treated mice. The results shown in Figure 4 indicate that the hepatic levels of cyclin D1 protein were almost undetectable in three out of four untreated mice; 2 days after tRA feeding a strong induction of cyclin D1 protein levels was seen, its expression being elevated over control values also at days 3, 4 and 5; levels of another G 1 cyclin, namely cyclin E, were also increased in tRA-fed mice although the peak of maximal expression was somewhat different (Figure 4) . Together with its partners CDK4 and CDK6, cyclin D1 is thought to stimulate entry into S phase by phosphorylating pRb and causing the release of components of the E2F family of transcription factors (33, 34) . Therefore, we have examined changes in the phosphorylation state of pRb and in the expression of its family members p107 and p130 on liver nuclear extracts of tRA-fed mice. Results shown in Figure 5 , demonstrated that p107 was enhanced in tRA-fed mice, with no major changes in the phosphorylative state of pRb and p130 expression. Finally, to determine whether the increased expression of p107 depends entirely on enhanced cyclin-associated CDK activities or could also be due to inhibition by tRA of the CDKs inhibitors p27 and p21, we measured the level of these proteins. As shown in Figure 5 , no significant difference in p21 was observed between untreated and tRA-fed mice, while p27 protein content was found to be higher than . Western blot analysis of pRb, p130, p107, p21 and p27 in mice killed 1, 2, 3, 4 and 5 days after treatment with tRA. Nuclear extracts for p130, pRb, p107, p21 and p27 (100--200 mg/lane) were prepared from the livers and western analysis was performed as described in the Materials and methods. Appropriate loading was confirmed by staining the gel with Coomassie Blue and using H3 antibody as loading control; efficiency of transfer was monitored by staining the membranes with Ponceau S red. Each lane represents pool of three livers. CO, controls. that of controls; these results clearly indicate that the increased p107 expression is not due to inhibition of the CDKs inhibitors.
The present study demonstrates that tRA exerts a clear stimulatory effect on hepatocyte proliferation in mice. The mitogenic effect exerted by tRA is not associated with liver injury but is a primary event leading to an increase in hepatic DNA content. Previous studies addressed to determine the effect of tRA on cell proliferation have produced conflicting results. Indeed, while tRA was shown to inhibit cell cycle progression in MCF-7 human breast cancer cells, most probably by downregulating cyclin D3/CDK4, pRb and E2F1 (35) , an increased number of normal hamster epithelial cells was observed after treatment with physiological concentrations of retinoic acid (36) . As to the liver, studies in rats have shown that tRA given shortly prior to 2/3 PH inhibited DNA synthesis in regenerating rat liver (14) , and that fast growing hepatomas showed depletion of retinoids (37) . Whether the different effect observed in the present study is due to the different species used (mouse versus rat) is unknown and deserves further studies.
There are two main points arising from this study: (i) the finding that tRA, together with thyroid hormone, peroxisome proliferators and the halogenated hydrocarbon TCPOBOP, ligands of the nuclear receptors RARs, TRs, PPARs and CAR, respectively, are all strong mitogens for rodent liver, supports the notion that nuclear receptors are, among several other biological effects, strongly involved in activating signal transducing pathways leading to cell cycle entry; (ii) the hepatomitogenic activity of tRA is in contrast to several previous studies suggesting a possible chemotherapeutic role of tRA in many types of cancer, based on its cytostatic effect. However, the finding of enhanced hepatocyte proliferation by tRA as demonstrated in this study, does not necessarily indicate that tRA has no antitumor effects. It is known that the great majority of preneoplastic nodules, after reaching a certain size, through replicative cell cycles, 'spontaneously' undergo re-differentiation to normal-appearing liver (remodelling), with a few remaining as precursor for the further development to cancer (38) . Although the mechanisms associated with re-differentiation of preneoplastic nodules are unknown, it is possible that agents capable of stimulating hepatocyte proliferation may also modulate genes involved in the redifferentiation programme, thus favouring the regression of preneoplastic lesions. In this respect, it is of interest the finding that another ligand of nuclear receptors, T3, accelerates regression of preneoplastic hepatic nodules and exerts an inhibitory effect on the development of hepatocellular carcinoma; these effects occur in spite of its mitogenic effect on normal and preneoplastic liver cells (39) , suggesting that T3 may induce a re-differentiation programme in preneoplastic hepatocytes. By virtue of the great differentiating capacity of RA, its possible induction of preneoplastic hepatocyte proliferation coupled with induction of a greater degree of re-differentiation of the nodules, might theoretically decrease the incidence of liver cancer. Thus, the experimental model of tRA-induced hepatocyte proliferation may serve useful for future analyses of the role of tRA on liver carcinogenesis.
